Jeffrey S. Farrow is CFO at Global Blood Therapeutics, Inc. (GBT). They have made 8 open-market trades across 2 companies since 2020, most recently 2026-06-16.
CIK 0001405253
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TARS | 56,801 | $3.9M |
| GBT | 26,739 | $1.8M |
| HPTX | 143,773 | — |
| RNVS | 62,286 | — |
| Total | $5.7M |
Shares reported on the most recent Form 4, priced at the 2026-06-17 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | SELL | 2026-06-16 | 2026-06-17 | $60.95 | $877K | +0.4% | -4.5% | +24.8% |
| TARS | SELL | 2026-03-17 | 2026-03-19 | $68.36 | $440K | +5.1% | -1.2% | -6.4% |
| TARS | SELL | 2025-06-17 | 2025-06-18 | $40.42 | $1.1M | -2.6% | +5.3% | +23.2% |
| TARS | SELL | 2025-03-18 | 2025-03-20 | $47.88 | $357K | -0.8% | -1.6% | -16.7% |
| TARS | SELL | 2024-06-18 | 2024-06-20 | $27.47 | $574K | +3.6% | +2.1% | +22.4% |
| GBT | SELL | 2022-09-01 | 2022-09-06 | $68.00 | $2.1M | -0.2% | N/A | N/A |
| GBT | SELL | 2020-07-13 | 2020-07-15 | $75.00 | $1.1M | -2.3% | -15.0% | -15.4% |
| GBT | SELL | 2020-06-09 | 2020-06-11 | $67.00 | $1.0M | +0.4% | +5.3% | -13.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.